Options
Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
Date Issued
2018-08-22
Date Available
2019-07-08T08:47:13Z
Abstract
Clinically used RAF inhibitors are ineffective in RAS-mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, post-translational modifications and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.
Sponsorship
European Commission Horizon 2020
Science Foundation Ireland
Type of Material
Journal Article
Publisher
Elsevier BV
Journal
Cell Systems
Volume
7
Issue
2
Start Page
161
End Page
179.e14
Copyright (Published Version)
2018 Elsevier
Language
English
Status of Item
Peer reviewed
ISSN
2405-4712
This item is made available under a Creative Commons License
File(s)
Owning collection
Scopus© citations
43
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Views
770
Last Month
2
2
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Downloads
357
Last Week
3
3
Last Month
5
5
Acquisition Date
Mar 28, 2024
Mar 28, 2024